Therapixel and Ferrum Health Announce Collaboration to Facilitate Access to Breast Imaging AI
Therapixel and Ferrum Health Collaboration Provides the Second Read for Breast Lesion Detection and Characterization on Screening Mammography.
Therapixel, a software company specializing in artificial intelligence (AI) applied to breast cancer screening, announced a partnership with Ferrum Health, the developer of a Healthcare AI Hub utilized by health systems to simplify and organized the deployment of artificial intelligence. Together, they bring life-saving AI technology to the early detection of breast cancer. Therapixel’s AI decision support for breast cancer screening is now available to Ferrum Health’s US-based clients, via the Ferrum Healthcare AI Hub. The collaboration brings Therapixel’s innovative AI software for mammography and Ferrum Health’s enterprise AI Hub to healthcare institutions and radiology practices looking to deploy breast health AI.
In this collaboration, Ferrum Health’s clients can access Therapixel software, MammoScreen® on their existing Ferrum Healthcare AI Hub and use it directly for concurrent reading decision support of screening mammograms or with Ferrum Health’s safety net program that provides a second reading service or assistance to quality teams during the peer-review of radiology studies.
“We are very excited to start this partnership with Ferrum Health. Technology alone cannot bridge the disparities of access to care. However, by supporting radiologists, it can contribute to saving lives. Artificial intelligence has the power to transform the way breast care is delivered, and this partnership with Ferrum Health will increase access to it,” said Matthieu Leclerc-Chalvet, CEO of Therapixel.
Recommended AI News: Merkle B2B Bolsters Creative Practice with Four Key Leadership Hires
“Our mission is to support health systems wanting to use AI to improve patient care,” said Pelu Tran, CEO of Ferrum Health. “Breast screening drives early breast cancer detection and we all know the impact of early detection on patient outcomes. Working with Therapixel, we hope to make AI a standard of care in all breast imaging programs.”
[To share your insights with us, please write to firstname.lastname@example.org]